{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Recombinases : Questions médicales les plus fréquentes",
"headline": "Recombinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Recombinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-06",
"dateModified": "2025-03-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Recombinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Enzymes",
"url": "https://questionsmedicales.fr/mesh/D004798",
"about": {
"@type": "MedicalCondition",
"name": "Enzymes",
"code": {
"@type": "MedicalCode",
"code": "D004798",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Holliday junction resolvases",
"alternateName": "Holliday Junction Resolvases",
"url": "https://questionsmedicales.fr/mesh/D045565",
"about": {
"@type": "MedicalCondition",
"name": "Holliday junction resolvases",
"code": {
"@type": "MedicalCode",
"code": "D045565",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.739.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Integrases",
"alternateName": "Integrases",
"url": "https://questionsmedicales.fr/mesh/D019426",
"about": {
"@type": "MedicalCondition",
"name": "Integrases",
"code": {
"@type": "MedicalCode",
"code": "D019426",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.739.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Recombinases",
"alternateName": "Recombinases",
"code": {
"@type": "MedicalCode",
"code": "D045522",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ahmed Abd El Wahed",
"url": "https://questionsmedicales.fr/author/Ahmed%20Abd%20El%20Wahed",
"affiliation": {
"@type": "Organization",
"name": "Division of Microbiology and Animal Hygiene, Georg-August University, D-37077 Goettingen, Germany."
}
},
{
"@type": "Person",
"name": "Jonas Kissenkötter",
"url": "https://questionsmedicales.fr/author/Jonas%20Kissenk%C3%B6tter",
"affiliation": {
"@type": "Organization",
"name": "Division of Microbiology and Animal Hygiene, Georg-August University, D-37077 Goettingen, Germany."
}
},
{
"@type": "Person",
"name": "Susanne Böhlken-Fascher",
"url": "https://questionsmedicales.fr/author/Susanne%20B%C3%B6hlken-Fascher",
"affiliation": {
"@type": "Organization",
"name": "Division of Microbiology and Animal Hygiene, Georg-August University, D-37077 Goettingen, Germany."
}
},
{
"@type": "Person",
"name": "Matthew S Forrest",
"url": "https://questionsmedicales.fr/author/Matthew%20S%20Forrest",
"affiliation": {
"@type": "Organization",
"name": "TwistDx(TM) Limited, Cambridge, United Kingdom."
}
},
{
"@type": "Person",
"name": "Maciej Paszkowski-Rogacz",
"url": "https://questionsmedicales.fr/author/Maciej%20Paszkowski-Rogacz",
"affiliation": {
"@type": "Organization",
"name": "Medical Systems Biology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Humphrey visual field made easy for residents.",
"datePublished": "2024-09-27",
"url": "https://questionsmedicales.fr/article/39331457",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4103/IJO.IJO_2519_23"
}
},
{
"@type": "ScholarlyArticle",
"name": "Detection of post-stroke visual field loss by quantification of the retrogeniculate visual pathway.",
"datePublished": "2022-05-27",
"url": "https://questionsmedicales.fr/article/35640329",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jns.2022.120297"
}
},
{
"@type": "ScholarlyArticle",
"name": "Foveal avascular zone vessel density is associated with visual field progression in early-stage glaucoma eyes with central visual field damage.",
"datePublished": "2023-10-25",
"url": "https://questionsmedicales.fr/article/37880406",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-45541-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Visual feedback in the lower visual field affects postural control during static standing.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35843008",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.gaitpost.2022.07.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Five-Year Visual Field Outcomes of the HORIZON Trial.",
"datePublished": "2023-02-21",
"url": "https://questionsmedicales.fr/article/36813144",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ajo.2023.02.008"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Recombinases",
"item": "https://questionsmedicales.fr/mesh/D045522"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Recombinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Recombinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Recombinases",
"description": "Comment diagnostiquer une déficience en recombinases ?\nQuels tests sont utilisés pour évaluer l'activité des recombinases ?\nLes symptômes peuvent-ils indiquer un problème de recombinases ?\nQuels marqueurs biologiques sont associés aux recombinases ?\nPeut-on détecter des recombinases par imagerie médicale ?",
"url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Recombinases",
"description": "Quels symptômes sont liés à une déficience en recombinases ?\nLes troubles de la recombinaison affectent-ils le système immunitaire ?\nY a-t-il des signes cliniques de dysfonction des recombinases ?\nLes cancers sont-ils liés aux anomalies des recombinases ?\nLes symptômes varient-ils selon le type de recombinase affectée ?",
"url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Recombinases",
"description": "Peut-on prévenir les troubles liés aux recombinases ?\nLes tests génétiques peuvent-ils aider à prévenir les troubles ?\nY a-t-il des recommandations pour les familles à risque ?\nL'éducation sur les maladies génétiques est-elle importante ?\nLes vaccinations peuvent-elles prévenir des complications ?",
"url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Recombinases",
"description": "Quels traitements existent pour les déficiences en recombinases ?\nPeut-on corriger les anomalies des recombinases par des médicaments ?\nLa thérapie génique est-elle efficace pour les troubles liés aux recombinases ?\nLes traitements préventifs sont-ils disponibles pour les troubles de recombinases ?\nLes greffes de cellules souches peuvent-elles aider ?",
"url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Recombinases",
"description": "Quelles complications peuvent survenir avec des troubles de recombinases ?\nLes troubles de recombinases augmentent-ils le risque de cancer ?\nComment les troubles de recombinases affectent-ils la qualité de vie ?\nLes complications sont-elles réversibles ?\nLes troubles de recombinases peuvent-ils affecter la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Recombinases",
"description": "Quels sont les facteurs de risque pour les troubles de recombinases ?\nL'exposition à des agents environnementaux influence-t-elle les troubles ?\nLes facteurs génétiques jouent-ils un rôle dans les troubles de recombinases ?\nLe sexe influence-t-il le risque de troubles de recombinases ?\nL'âge est-il un facteur de risque pour les troubles de recombinases ?",
"url": "https://questionsmedicales.fr/mesh/D045522?mesh_terms=Visual+Fields&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en recombinases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de l'ADN peuvent identifier des anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des recombinases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de recombinaison in vitro et des analyses de séquençage sont courants."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils indiquer un problème de recombinases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies immunitaires ou des troubles génétiques peuvent être des indicateurs."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux recombinases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de certains ARN ou protéines peuvent signaler des dysfonctionnements."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des recombinases par imagerie médicale ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'imagerie ne peut pas détecter directement les recombinases, mais elle aide à évaluer les effets."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une déficience en recombinases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections fréquentes, des troubles auto-immuns et des cancers peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les troubles de la recombinaison affectent-ils le système immunitaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent entraîner une immunodéficience et une susceptibilité accrue aux infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques de dysfonction des recombinases ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans les tests sanguins et des symptômes d'inflammation peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les cancers sont-ils liés aux anomalies des recombinases ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans les gènes de recombinases peuvent augmenter le risque de cancers."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de recombinase affectée ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent du type de recombinase et de son rôle dans l'organisme."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux recombinases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à prévenir les troubles ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques permettent d'identifier les porteurs et de planifier des interventions."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les familles à risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conseils génétiques et le suivi médical régulier sont recommandés pour les familles à risque."
}
},
{
"@type": "Question",
"name": "L'éducation sur les maladies génétiques est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une meilleure compréhension des maladies génétiques peut aider à la prévention et à la gestion."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles prévenir des complications ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent réduire le risque d'infections chez les patients immunodéficients."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les déficiences en recombinases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies géniques et les traitements immunologiques sont des options possibles."
}
},
{
"@type": "Question",
"name": "Peut-on corriger les anomalies des recombinases par des médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de médicaments spécifiques pour corriger ces anomalies."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle efficace pour les troubles liés aux recombinases ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent des résultats prometteurs, mais des recherches supplémentaires sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les traitements préventifs sont-ils disponibles pour les troubles de recombinases ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitements préventifs, mais un suivi médical régulier est recommandé."
}
},
{
"@type": "Question",
"name": "Les greffes de cellules souches peuvent-elles aider ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent être bénéfiques pour certains patients avec des troubles immunitaires liés."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des troubles de recombinases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections récurrentes, des cancers et des troubles auto-immuns sont possibles."
}
},
{
"@type": "Question",
"name": "Les troubles de recombinases augmentent-ils le risque de cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans les gènes de recombinases sont souvent associées à divers cancers."
}
},
{
"@type": "Question",
"name": "Comment les troubles de recombinases affectent-ils la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent entraîner des limitations physiques, des hospitalisations fréquentes et des douleurs."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Les troubles de recombinases peuvent-ils affecter la fertilité ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles peuvent avoir un impact sur la fertilité, nécessitant une évaluation."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles de recombinases ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux de maladies génétiques et des mutations spécifiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'exposition à des agents environnementaux influence-t-elle les troubles ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains agents environnementaux peuvent augmenter le risque de mutations génétiques."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle dans les troubles de recombinases ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations héréditaires dans les gènes de recombinases sont souvent impliquées."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de troubles de recombinases ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines conditions peuvent être plus fréquentes chez un sexe, mais cela varie selon les maladies."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour les troubles de recombinases ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles peuvent se manifester plus tard dans la vie, augmentant le risque avec l'âge."
}
}
]
}
]
}
Visual field testing is an indispensable part of the assessment of glaucoma. Of paramount importance to both the practitioner and the perimetrist is the guidance on how to conduct the test to get the ...
To simplify the basics of understanding single-field analysis of visual field tests by using the Humphrey perimeter....
The general principle and a brief overview of how the Humphrey visual field is conducted and the approach to interpreting the results of single field analysis in an easy-to-understand manner are prese...
This educational video is an attempt to simplify the interpretation of Humphrey visual field single-field analysis with illustrations and video clips that would be useful to practicing ophthalmologist...
https://youtu.be/x8iZLDR4XdY....
Visual field loss is associated with poor post-stroke functional outcomes. However, early detection of visual field loss is often challenging in patients with disabling stroke. This study explored the...
We investigated the relationship between foveal avascular zone (FAZ)-related parameters, assessed by optical coherence tomography angiography (OCT-A), and visual field (VF) progression in early-stage ...
The dorsal parietal visual system plays an important role in self-motion perception and spatial cognition. It also strongly responds to visual inputs from the lower visual field. Postural control is m...
Do visual stimuli presented to the lower and upper visual fields affect postural control and sensory reweighting?...
Twenty-nine healthy young adults participated in the study. Four conditions (full visual field, upper visual field, lower visual field, and no optic flow condition) were simulated in a VR environment ...
Optic flow in the full and lower visual fields produced significantly smaller 95 % ellipse area and RMS of COP in the anterior-posterior direction compared to optic flow in the upper visual field. Furth...
Visual feedback affects static postural control more when presented in the lower visual field compared to the upper visual field....
To compare visual field (VF) progression between glaucoma patients receiving cataract surgery alone (CS) or with a Hydrus microstent (CS-HMS)....
Post hoc analysis of VF data from the HORIZON multicenter randomized controlled trial....
A total of 556 patients with glaucoma and cataract were randomized 2:1 to either CS-HMS (369) or CS (187) and followed up for 5 years. VF was performed at 6 months and then every year after surgery. W...
Data from 352 eyes in the CS-HMS arm and 165 in the CS arm were analyzed (2966 VFs). The mean RoP was -0.26 dB/y (95% credible interval -0.36, -0.16) for CS-HMS and -0.49 dB/y (95% credible interval -...
CS-HMS has a significant effect on VF preservation in glaucoma patients compared with CS alone, reducing the proportion of fast progressors....
This study quantifies the effect of trabeculectomy on the rate of progression (RoP) of visual field (VF) damage utilising pre- and post-operative visual function as the outcome instead of surrogate ou...
Clinical and VF data from 199 sequential patients who underwent trabeculectomy between 2015 and 2016 were extracted from the network of sites of Moorfields Eye Hospital NHS Foundation Trust. Of these,...
We analysed 10 [9,12] VFs per subject (Median [Interquartile Range]). At surgery, the age was 67 [57, 72] years, mean deviation was -10.84 [-14.7, -5.6] dB and the IOP was 18 [15, 20] mmHg. One year a...
Trabeculectomy leads to a significant reduction in the RoP of VF loss postoperatively....
A multitude of terms have been used to describe automated visual field abnormalities. To date, there is no universally accepted system of definitions or guidelines. Variability among clinicians create...
In phase one of the study, all neuro-ophthalmologists in Israel were asked to complete a survey in which they described the abnormalities in 10 selected automated visual field tests. In phase 2 of the...
Twenty-six neuro-ophthalmologists participated in the initial survey. On average, there were 7.5 unique descriptions for each of the visual fields (SD 3.17), a description of only the location in 24.6...
The study confirmed a great degree of variability in the use of terminology to describe automated visual field abnormalities. The creation of a consensus statement was associated with improved use of ...
To determine the usefulness of Humphrey Field Analyser (HFA) SITA-Faster 24-2 gaze tracker outputs on interpreting intra-visit visual field (VF) result pairs....
Analysis of 1380 right-left eye pairs and 1432 pairs of test 1-test 2 intrasession VF results of patients seen within a university-based glaucoma service was undertaken to understand gaze deviation di...
There was no association of test order (right-left, test 1-test 2) with eye movements. There was a significant, but weak correlation between eye movements and age (r = 0.16). Correlations of eye movem...
Eye movement parameters as currently reported by the HFA do not appear to be correlated with key sensitivity parameters when considering the repeatability of intrasession SITA-Faster 24-2 VF results. ...
Peripheral visual field (VF) loss affects 13% of the population over 65. Its effect on activities of daily living and higher order visual processing is as important as it is inadequately understood. T...
In this review, glaucoma and retrochiasmal cortical damage are utilized as examples of peripheral field loss which typically spare central vision and have patterns respecting the horizontal and vertic...
Peripheral VF loss is an under-recognized cause of patient distress and disability. All peripheral field loss is not the same, differential patterns of loss affect parameters of activities of daily li...
A central question in neuroscience is how the organization of cortical maps relates to perception, for which human primary visual cortex (V1) is an ideal model system. V1 nonuniformly samples the reti...